A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer

A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting

“…According to Japanese studies (24), Taiwanese studies (25) and our study, far-east Asian patients appear to have poorer tolerance and greater hematologic toxicities with docetaxelbased treatment compared with western patients. Taiwanese and Japanese studies have also concluded that the addition of ifosfamide to docetaxel for NSCLC patients should not be recommended either as the first-line or second-line chemotherapy due to the severe hematologic toxicities (24,25).…”

“…Taiwanese and Japanese studies have also concluded that the addition of ifosfamide to docetaxel for NSCLC patients should not be recommended either as the first-line or second-line chemotherapy due to the severe hematologic toxicities (24,25). Based on our study, the hematologic toxicity for the docetaxel and ifosfamide combination chemotherapy was just too severe to continue applying this treatment in this salvage setting.…”

“…In another study using docetaxel plus ifosfamide and cisplatin in chemo-naïve NSCLC patients, it was shown that the majority of the chemotherapy courses had to be supported by G-CSF administration, and the clinical efficacy of this regimen does not seem to justify the toxicity profile (24).…”

Ifosfamide in Non-Small Cell Lung Cancer

“…Two other trials, with a lower dose level of drugs, showed conflicting results. Kunitoh et al [43]in a phase I–II trial found a 30% response rate in 33 patients, with a relevant toxicity in absence of prophylactic G-CSF; to note that the schedule required the uncommon sequence of cisplatin on day 1 followed by ifosfamide on days 2–4. The Irish Group, ICORG [44], in 33 patients again, obtained a response rate exceeding 60%, with 1-year survival of 53% and acceptable toxicity using lenograstim support.…”

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer?

“…1,2 The most often used regimens have similar efficacy, but the toxicity of these regimens may adversely affect the patient's quality of life (QOL). [3][4][5][6] Chemotherapy-induced neutropenia is the primary dose-limiting and potentially life-threatening complication in patients with NSCLC treated with chemotherapy. Grade 4 neutropenia occurs in 38% to 59% of patients and febrile neutropenia in up to 10%.…”